Sept 29 (Reuters) – Metsera Inc: * METSERA REPORTS POSITIVE PHASE 2B RESULTS FOR FIRST- AND BEST-IN-CLASS ULTRA-LONG ACTING GLP-1 RA CANDIDATE MET-097I, ENABLING RAPID TRANSITION INTO PHASE 3 * METSERA INC – MET-097I SHOWS 14.1% WEIGHT LOSS AFTER 28 WEEKS * METSERA INC – MET-097I SHOWS CLASS-LEADING TOLERABILITY IN TRIALS * METSERA INC – DATA SUPPORTS PHASE 3 INITIATION IN LATE 2025 Source text: Further company coverage: ;))
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
If you feel tired, cold all the time or have brittle nails, this may be…
Despite living in a tech-paced environment, for many viewers, movies and TV shows remain inaccessible. Meet the…
Berlin (dpa) – Bloodshed comes fast to the screen in the historical drama "The Uprising,"…
Despite living in a tech-paced environment, for many viewers, movies and TV shows remain inaccessible. Meet the…
In the drama "Gentle Monster", Jella Haase investigates a case of child abuse and shares…
Los Angeles (dpa) - Scientists have named four newly identified insect species after US pop…